← Back to Calendar

Relay Therapeutics Q4 2025 Earnings

Relay Therapeutics · $RLAY

Standard Review Earnings

PDUFA Date

February 26, 2026

Time Remaining

26d ago

Review Type

Standard (10 mo)

Indication

Q4 2025 earnings + zovegalisib SERENA-PI3K update

Key Notes

Q4 2025 earnings reported February 26, 2026. Cash: ~$555M at end of Q4 2025. RLY-2608 renamed to zovegalisib following Breakthrough Therapy designation. Initial Phase 1/2 data at ESMO TAT March 16, 2026. Full SERENA-PI3K Phase 2 readout expected H1 2026 (ASCO). Breast cancer triplet data and Phase 3 plans expected 2026.

⚠️ Not Investment Advice: This information is provided for educational purposes only. PDUFA dates are FDA target action dates, not guaranteed approval dates. The FDA may extend the review period, issue Complete Response Letters, or take unexpected actions. Probability of approval scores are based on historical base rates and do not account for drug-specific factors. Always consult a financial advisor before making investment decisions.

← Back to Full Calendar